Only two of the EZH2 mutation-positive individuals we report have developed malignancies; case 8 who carries a de novo missense mutation, A682T, in the SET domain, developed neuroblastoma and acute lymphoblastic lymphoma, both diagnosed at 13 months. This evidence concerns the gene EZH2 and neuroblastoma.